Katakura R, Mori T, Suzuki J
No Shinkei Geka. 1982 Sep;10(9):941-4.
The authors have developed a new dosage-form using a water soluble anticancer drug, Bleomycin (BLM), which had prolonged releasing properties exceeding for 15 days in vivo for intracranial administration. Basic experiments using these tablets have been previously reported. This study evaluates the anti-cancer effect of the tablets and its clinical application. For the evaluation of the anti-cancer effect, glioma cells were transplanted into the peritoneal cavity of Wister rats. The rats were divided into 4 main groups and treated by as follows: 1) BLM tablets (1 mg.P) implantation in the peritoneal cavity, 2) Placebo implantation, 3) Bleomycin solution (total 1 mg. P) injection and 4) physiological saline solution injection (The control). The group treated with BLM tablets showed the best results. Clinical application of BLM tablets was performed in 6 patients of craniopharyngioma. During operation, the tablets were placed into tumor cavity by alon-alpha. In one case, recurrence was greatly prolonged. This tablet is considered to usable for the treatment of cancer in not only the field of neurosurgery but also in other fields.
作者研发了一种新剂型，使用水溶性抗癌药物博来霉素（BLM），该剂型经颅内给药后在体内具有超过15天的缓释特性。此前已报道了使用这些片剂的基础实验。本研究评估了该片剂的抗癌效果及其临床应用。为评估抗癌效果，将胶质瘤细胞移植到Wistar大鼠的腹腔中。大鼠分为4个主要组并按以下方式进行治疗：1）将BLM片剂（1mg.P）植入腹腔，2）植入安慰剂，3）注射博来霉素溶液（总量1mg.P），4）注射生理盐水溶液（对照组）。用BLM片剂治疗的组显示出最佳效果。对6例颅咽管瘤患者进行了BLM片剂的临床应用。手术过程中，通过alon-alpha将片剂放入肿瘤腔。在1例患者中，复发时间大大延长。该片剂被认为不仅可用于神经外科领域的癌症治疗，也可用于其他领域。
